Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

Company Overview and News

Perisai Petroleum's restraining order extended by nine months

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): Perisai Petroleum Teknologi Bhd has received a nine-month extension from the Kuala Lumpur High Court to restrain all proceedings and actions brought against the Practice Note 17 (PN17) company.
0047 BSMAF 1818

KLCI down 0.38% as regional markets turn choppy

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI fell 0.38% at the midday break today against the backdrop of choppy regional markets, dragged by select index-linked blue chips.
HLFBF 7251 MLYBY MLYNF UPBMF 1082 7113 5032 8664 TPGVF BATS 4162 2089 9334 2852 TGLVY 1155 0047 5347 3301 TNABY TNABF GEBHF

KLCI remains under pressure as select blue chips weigh

2018-06-12 theedgemarkets
KUALA LUMPUR (June 12): The FBM KLCI remained under pressure at mid-morning today, dragged by select index-linked blue chips.
HLFBF 7251 UPBMF 1082 7113 5032 TPGVF BATS 4162 7153 5168 2089 9334 TGLVY 5139 0047 5347 3026 0104 0900 6645 TNABY TNABF HRGHY

KLCI reverses loss, rises 0.54%

2018-06-11 theedgemarkets
KUALA LUMPUR (June 11): The FBM KLCI reversed its earlier losses and rose 0.54% at the midday break, tracking gains at most regional markets.
7251 7113 5681 TPGVF 7153 7077 9334 6033 2186 CIMDF 0166 TGLVY 1023 0047 PNADF 3026 2836 PNAGF

Perisai Petroleum’s creditors approve scheme of arrangement

2018-06-08 theedgemarkets
KUALA LUMPUR (June 8): Practice Note 17(PN17) company Perisai Petroleum Teknologi Bhd’s creditors today gave their approval to the proposed scheme of arrangement presented by the company.
0047 BSMAF 1818

Trading ideas: KPS, Perisai, GSB Group

2018-05-21 - 1
KUALA LUMPUR: Kumpulan Perangsang Selangor Bhd , Perisai Petroleum Teknologi Bhd and GSB Group Bhd are among the stocks to watch on Monday, according to JF Apex Research.
5843 0047 7077

Recovery in crude oil prices yet to have big impact on players

Steady path: Gas prices are displayed at a Mobil station in New York. Crude oil prices have risen steadily by more than 10. Shares in oil majors, including Exxon Mobil, have surged. — AP
7293 7251 RDS.B RDS.A BRDBF XOM 5141 RDSB RDSA 7164 5210 0047 7206 7108 RYDBF RYDAF

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="